Phase 2 Alzheimer's Disease Trial, Not Yet Recruiting NCT07579884 Sponsor: Risen (Suzhou) Pharma Tech Co., Ltd. Condition: Alzheimer's Disease
Back to Alzheimers Disease

Phase 2 Alzheimer's Disease Trial, Not Yet Recruiting

NCT07579884
Not Yet Recruiting Phase 2

voxsanity.com.au · Eligibility summary from public government registries · 18 August 2026 · not medical advice

Who may and may not be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who may be able to join

  • People who are participating voluntarily and have signed a consent form agreeing to take part.
  • People who have completed at least junior high school and are able to complete memory and thinking tests as required by the study.
  • People who meet the official 2024 diagnostic criteria for mild cognitive impairment (MCI) set by the National Institute on Aging-Alzheimer's Association (NIA-AA).
  • People whose scores on standard memory and thinking tests fall within a specific range: a Mini-Mental State Examination (MMSE) score of 24 or higher, a Clinical Dementia Rating Global Score of 0.5, and a memory sub-score of 0.5 or higher (confirm with trial site).
  • People whose score on a standard depression rating scale (the 17-item Hamilton Depression Rating Scale) is 10 or below, indicating low levels of depression symptoms.
  • People whose score on the Hachinski Ischemic Scale is 4 or below, a measure used to help identify the likely cause of memory problems (confirm with trial site).

Who may not be able to join

Each point below is a reason the trial team may not be able to accept someone. It is not a list of requirements to meet.

  • People whose dementia or memory problems are caused by something other than Alzheimer's disease.
  • People who have a neurological (brain or nervous system) condition other than Alzheimer's disease.
  • People with certain active infections, including specific forms of hepatitis B, hepatitis C, HIV, or syphilis, as detected by blood tests.
  • People who have an active infection — bacterial, viral, fungal, or parasitic — that the trial doctor considers significant.
  • People whose heart rhythm test (ECG) shows a measurement called QTcF above 450 ms for males or above 470 ms for females, or any other significant heart rhythm abnormality the trial doctor considers a concern.
  • People who have had severe or poorly managed heart, lung, digestive, urinary, blood, hormonal, or neurological conditions (other than Alzheimer's disease) in the six months before the screening visit.
  • People who have had an active peptic ulcer, inflammatory bowel disease, or another serious gut condition affecting how medication is absorbed in the six months before screening, or who have had gastrointestinal bleeding, a perforation, or gut surgery in the past five years (not including appendix removal, polyp removal, or haemorrhoid surgery).
  • People who have been diagnosed with a malignant (cancerous) tumour in the three years before screening, with some exceptions for certain cured or surgically removed skin cancers (confirm with trial site).
  • People who have taken part in another clinical trial within three months before being assigned to a study group, although participation in an observational study with no interference may be allowed at the trial doctor's discretion.
  • People who have had a problem with alcohol or drug misuse in the year before the screening visit.
  • People with a history of severe allergic reactions to medications, or allergies to multiple medications.
  • Women who are currently breastfeeding.
  • People the trial doctor considers unsuitable for the study for any other reason.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 5 August 2026

Contact this trial

Principal Investigator: Yi Tang, Xuanwu Hospital, Beijing

Phone: *86 21-61910060

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Not Yet Recruiting
Phase
Phase 2
Sponsor
Risen (Suzhou) Pharma Tech Co., Ltd.
Registry
ClinicalTrials.gov
Start date
1 July 2026
Est. completion
1 May 2029

Primary endpoints

Clinical Dementia Rating Scale - Sum of Boxes

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 5 August 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov